SLC5A2 and diabetes mellitus: <h4>Introduction</h4>The FIDELITY pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials showed a complementary benefit of finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D).